Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación

Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials

  • González Gil, Celia|||0000-0002-7582-1482
  • Morgades, Mireia|||0000-0003-0295-2534
  • Lopes, Thaysa|||0000-0003-1522-6312
  • Fuster-Tormo, Francisco|||0000-0002-1220-6183
  • Montesinos, Pau|||0000-0002-3275-5593
  • Barba, Pere|||0000-0001-7076-7969
  • Díaz-Beyá, Marina|||0000-0001-9624-2597
  • Hermosín, Lourdes
  • Maluquer, Clara
  • González Campos, José
  • Bernal, Teresa|||0000-0002-2338-513X
  • Arriaga, Marta Sitges
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Pratcorona, Marta|||0000-0001-6375-596X
  • Martino Bofarull, Rodrigo|||0000-0001-5143-4042
  • Larrayoz, María José
  • Artola, Teresa
  • Torrent Catarineu, Anna|||0000-0002-3727-5716
  • Vall-Llovera, Ferran|||0000-0002-0718-5955
  • Tormo, Mar|||0000-0001-9622-1649
  • Gil, Cristina
  • Novo, Andrés
  • Martínez Sánchez, Pilar|||0000-0002-7334-140X
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • Queipo, María-Paz
  • González-Martínez, Teresa
  • Cabrero, Mónica
  • Cladera, Antonia
  • Cervera, José|||0000-0001-8252-1106
  • Orfao, Alberto|||0000-0002-0007-7230
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Genescà, Eulàlia|||0000-0002-5657-4842
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Single-Cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy

  • Campillo-Marcos, Ignacio|||0000-0002-7657-7127
  • Casado Pelaez, Marta|||0000-0002-8428-8384
  • Davalos, Veronica|||0000-0003-4077-5137
  • Ferrer, Gerardo|||0000-0002-4084-6815
  • Mata, Caterina|||0000-0001-9403-7434
  • Mereu, Elisabetta|||0000-0001-6101-8472
  • Roué, Gaël|||0000-0003-0245-2257
  • Valcárcel, David|||0000-0002-8747-078X
  • Molero, Antonieta|||0000-0002-3735-465X
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Xicoy, Blanca|||0000-0002-0295-1307
  • Palomo Sanchís, Laura|||0000-0003-3176-6271
  • Acha, Pamela|||0000-0002-4528-1219
  • Manzanares Mileo, Ana|||0000-0003-4125-4675
  • Tobiasson, Magnus|||0000-0002-3633-5852
  • Hellström-Lindberg, Eva|||0000-0002-7839-3743
  • Sole, F|||0000-0002-3251-2161
  • Esteller, M|||0000-0003-4490-6093
Alterations in epigenetic marks, such as DNA methylation, represent a hallmark of cancer that has been successfully exploited for therapy in myeloid malignancies. Hypomethylating agents (HMAs), such as azacitidine (AZA), have become standard-of-care therapy to treat myelodysplastic syndromes (MDS), myeloid neoplasms that can evolve into acute myeloid leukemia (AML). However, our capacity to identify who will respond to HMAs, and the duration of response, remains limited. To shed light on this question, we have leveraged the unprecedented analytical power of single-cell technologies to simultaneously map the genome and immunoproteome of MDS samples throughout clinical evolution. We were able to chart the architecture and evolution of molecular clones in precious paired bone marrow MDS samples at diagnosis and post-treatment to show that a combined imbalance of specific cell lineages with diverse mutational profiles is associated with the clinical response of MDS patients to hypomethylating therapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The stem region of group A transferase is crucial for its specificity, and its alteration promotes heterologous Forssman synthase activity

  • Cid, Emili|||0000-0002-5025-352X
  • Yamamoto, Miyako|||0000-0001-9516-1402
  • Barrero, Laura
  • Yamamoto, Fumiichiro|||0000-0001-9690-7034
Some stem region mutants of human blood group A transferase (hAT) possess Forssman synthase (FS) activity, but very little is known about the mechanisms responsible for this enzymatic crosstalk. We performed confocal microscopy and image analysis to determine whether different intra-Golgi localization was accountable for this acquired activity. We also performed structural modeling and mutational and normal mode analyses. We introduced new mutations in the stem region and tested its FS and AT activities. No differences in subcellular localization were found between hAT and FS-positive mutants. AlphaFold models of hAT and mFS (mouse Forssman synthase) showed that the hAT stem region has a tether-like stem region, while in mFS, it encircles its catalytic domain. In silico analysis of FS-positive mutants indicated that stem region mutations induced structural changes, decreasing interatomic interactions and mobility of hAT that correlated with FS activity. Several additional mutations introduced in that region also bestowed FS activity without altering the AT activity: hAT 37-55 aa substitution by mFS 34-52, 37-55 aa deletion, and missense mutations: S46P, Q278Y, and Q286M. Stem region structure, mobility, and interactions are crucial for hAT specificity. Moreover, stem region mutations can lead to heterologous Forssman activity without changes in the catalytic machinery.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide

  • Serrano, Guillermo|||0000-0003-3972-6186
  • Berastegui, Nerea|||0000-0002-9868-0547
  • Díaz-Mazkiaran, Aintzane
  • García-Olloqui, Paula|||0000-0002-7983-2875
  • Rodriguez-Res, Carmen
  • Huerga-Dominguez, Sofia
  • Ainciburu, Marina|||0000-0001-6483-1901
  • Vilas-Zornoza, Amaia|||0000-0001-6693-0989
  • Martin-Uriz, Patxi San|||0000-0003-1483-4279
  • Aguirre-Ruiz, Paula
  • Ullate-Agote, Asier|||0000-0002-8595-7703
  • Ariceta, Beñat|||0000-0001-8819-402X
  • Lamo-Espinosa, Jose-Maria
  • Acha, Pamela|||0000-0002-4528-1219
  • Calvete, Oriol|||0000-0002-2623-2876
  • Jimenez, Tamara|||0000-0001-5894-2023
  • Molero, Antonieta|||0000-0002-3735-465X
  • Montoro Gómez, Maria Julia|||0000-0001-9532-7417
  • Diez-Campelo, María|||0000-0002-1467-6779
  • Valcárcel, David|||0000-0002-8747-078X
  • Sole, F.|||0000-0002-3251-2161
  • Alfonso-Piérola, Ana|||0000-0002-2478-5354
  • Ochoa, Idoia|||0000-0003-1864-7868
  • Prosper, Felipe|||0000-0001-6115-8790
  • Ezponda, Teresa|||0000-0003-3682-7125
  • Hernaez, Mikel|||0000-0003-0443-2305
While myelodysplastic syndromes with del(5q) (del(5q) MDS) comprises a well-defined hematological subgroup, the molecular basis underlying its origin remains unknown. Using single cell RNA-seq (scRNA-seq) on CD34 + progenitors from del(5q) MDS patients, we have identified cells harboring the deletion, characterizing the transcriptional impact of this genetic insult on disease pathogenesis and treatment response. Interestingly, both del(5q) and non-del(5q) cells present similar transcriptional lesions, indicating that all cells, and not only those harboring the deletion, may contribute to aberrant hematopoietic differentiation. However, gene regulatory network (GRN) analyses reveal a group of regulons showing aberrant activity that could trigger altered hematopoiesis exclusively in del(5q) cells, pointing to a more prominent role of these cells in disease phenotype. In del(5q) MDS patients achieving hematological response upon lenalidomide treatment, the drug reverts several transcriptional alterations in both del(5q) and non-del(5q) cells, but other lesions remain, which may be responsible for potential future relapses. Moreover, lack of hematological response is associated with the inability of lenalidomide to reverse transcriptional alterations. Collectively, this study reveals transcriptional alterations that could contribute to the pathogenesis and treatment response of del(5q) MDS. The hematopoiesis of patients with del(5q) Myelodysplastic Syndromes is composed of a mixture of cells with and without the deletion. Here, the authors show that del(5q) and non-del(5q) cells share similar transcriptional alterations, with del(5q) cells presenting additional lesions. Moreover, hematological response to lenalidomide is associated with the reversal of some transcriptional lesions in both del(5q) and non-del(5q) cells.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

A framework for the clinical implementation of optical genome mapping in hematologic malignancies

  • Levy, Brynn|||0000-0002-4213-3480
  • Kanagal-Shamanna, Rashmi|||0000-0001-7829-5249
  • Sahajpal, Rashmi Kanagal
  • Neveling, Nikhil S.
  • Rack, Katrina
  • Dewaele, Barbara|||0000-0002-1183-5228
  • Olde Weghuis, Daniel
  • Stevens-Kroef, Marian
  • Puiggros, Anna|||0000-0001-9627-4978
  • Mallo, Maria del Mar|||0000-0001-7741-498X
  • Clifford, Benjamin
  • Mantere, Tuomo
  • Hoischen, Alexander
  • Espinet Solà, Blanca|||0000-0002-4294-8145
  • Kolhe, Ravindra|||0000-0002-8283-2403
  • Sole, F.|||0000-0002-3251-2161
  • Raca, Gordana|||0000-0002-3521-9585
  • Smith, Adam C.|||0000-0001-9927-4914
Optical Genome Mapping (OGM) is rapidly emerging as an exciting cytogenomic technology both for research and clinical purposes. In the last 2 years alone, multiple studies have demonstrated that OGM not only matches the diagnostic scope of conventional standard of care cytogenomic clinical testing but it also adds significant new information in certain cases. Since OGM consolidates the diagnostic benefits of multiple costly and laborious tests (e.g., karyotyping, fluorescence in situ hybridization, and chromosomal microarrays) in a single cost-effective assay, many clinical laboratories have started to consider utilizing OGM. In 2021, an international working group of early adopters of OGM who are experienced with routine clinical cytogenomic testing in patients with hematological neoplasms formed a consortium (International Consortium for OGM in Hematologic Malignancies, henceforth "the Consortium") to create a consensus framework for implementation of OGM in a clinical setting. The focus of the Consortium is to provide guidance for laboratories implementing OGM in three specific areas: validation, quality control and analysis and interpretation of variants. Since OGM is a complex technology with many variables, we felt that by consolidating our collective experience, we could provide a practical and useful tool for uniform implementation of OGM in hematologic malignancies with the ultimate goal of achieving globally accepted standards.